Akebia Therapeutics (AKBA) Financials: History & Chart

Akebia Therapeutics, Inc.(AKBA)

Biotechnology · Waltham, MA

$0.88-0.03 (-3.35%)

Delayed quote: Oct 6, 2026, 10:15 AM EDT

About Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.

Waltham, MA

194 employees

www.akebia.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: John Butler

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	219.06M	49.13M	53.54M	57.62M	58.77M	62.47M	57.34M	46.50M	37.43M
Cost of Goods Sold	44.96M	10.42M	12.62M	12.22M	9.70M	9.92M	7.63M	20.36M	14.16M
Gross Profit	174.10M	38.70M	40.93M	45.41M	49.06M	52.55M	49.71M	26.13M	23.27M
Gross Profit Margin	79.5%	78.8%	76.4%	78.8%	83.5%	84.1%	86.7%	56.2%	62.2%
Total Operating Expenses	189.22M	45.03M	45.62M	53.96M	44.62M	38.46M	36.20M	40.44M	35.77M
Research & Development	70.14M	14.06M	14.81M	26.65M	14.63M	11.01M	9.75M	11.79M	8.49M
Selling, General & Administrative	114.69M	28.17M	30.44M	26.09M	29.99M	26.55M	25.74M	27.68M	26.52M
Operating Income (EBIT)	-15.13M	-6.33M	-4.70M	-8.55M	4.45M	14.09M	13.51M	-14.31M	-12.51M
Operating Margin	-6.9%	-12.9%	-8.8%	-14.8%	7.6%	22.6%	23.6%	-30.8%	-33.4%
Income Before Tax (EBT)	-27.85M	-8.84M	-8.93M	-11.23M	1.16M	247K	6.11M	-22.80M	-20.04M
Interest Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	7.96M	3.07M	-4.69M	4.83M	4.75M	6.83M	7.77M	6.88M	6.66M
Other Income/Expense	-12.72M	-2.51M	-4.23M	-2.68M	-3.29M	-13.84M	-7.40M	-8.50M	-7.53M
Net Income	-29.67M	-8.91M	-9.05M	-12.24M	540K	247K	6.11M	-22.80M	-20.04M
Income Tax Expense	1.82M	70K	126K	1.01M	615K	0.00	0.00	0.00	0.00
Net Profit Margin	-13.5%	-18.1%	-16.9%	-21.2%	0.9%	0.4%	10.7%	-49.0%	-53.5%
EBITDA	-13.25M	-5.41M	-4.37M	-8.23M	4.77M	14.40M	13.83M	-4.96M	-3.13M
EBITDA Margin	-6.0%	-11.0%	-8.2%	-14.3%	8.1%	23.1%	24.1%	-10.7%	-8.4%
Depreciation & Amortization	1.88M	913K	328K	321K	318K	316K	314K	9.35M	9.37M
EPS Basic	-0.11	-0.03	-0.03	-0.05	0.00	0.00	0.03	-0.10	-0.10
EPS Diluted	-0.11	-0.03	-0.03	-0.05	0.00	0.00	0.03	-0.10	-0.10
Weighted Average Basic Shares	269.60M	269.60M	267.05M	265.37M	264.79M	262.57M	235.50M	218.70M	210.35M
Weighted Average Diluted Shares	269.60M	269.60M	267.05M	265.37M	274.37M	271.10M	241.60M	218.70M	210.35M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	236.20M	160.18M	194.62M	292.48M	211.65M	294.64M	335.00M	207.74M
Cost of Goods Sold	39.46M	63.18M	74.15M	22.50M	81.49M	63.96M	145.34M	7.68M
Gross Profit	196.73M	97.00M	120.47M	269.99M	130.16M	230.68M	189.66M	200.06M
Gross Profit Margin	83.3%	60.6%	61.9%	92.3%	61.5%	78.3%	56.6%	96.3%
Total Operating Expenses	173.24M	147.47M	166.73M	350.77M	394.66M	608.51M	475.95M	378.20M
Research & Development	62.36M	37.65M	63.08M	165.99M	147.85M	218.49M	322.97M	291.07M
Selling, General & Administrative	107.48M	106.55M	100.23M	138.60M	174.14M	154.10M	149.46M	87.06M
Operating Income (EBIT)	23.50M	-50.47M	-46.26M	-80.78M	-264.50M	-377.83M	-286.29M	-178.14M
Operating Margin	9.9%	-31.5%	-23.8%	-27.6%	-125.0%	-128.2%	-85.5%	-85.8%
Income Before Tax (EBT)	-3.72M	-69.41M	-51.92M	-94.23M	-282.02M	-384.84M	-286.29M	-171.90M
Interest Income	N/A	N/A	N/A	N/A	N/A	N/A	2.19M	6.15M
Interest Expense	24.18M	18.18M	6.03M	15.69M	19.94M	8.87M	1.40M	N/A
Other Income/Expense	-27.22M	-18.94M	-5.67M	-13.45M	-17.52M	-7.01M	-2K	6.24M
Net Income	-5.34M	-69.41M	-51.92M	-94.23M	-282.02M	-384.84M	-279.66M	-171.90M
Income Tax Expense	1.62M	0.00	0.00	0.00	0.00	0.00	-6.63M	-28.34M
Net Profit Margin	-2.3%	-43.3%	-26.7%	-32.2%	-133.3%	-130.6%	-83.5%	-82.7%
EBITDA	24.77M	-12.97M	-8.63M	-43.08M	-226.53M	-343.13M	-249.87M	-175.72M
EBITDA Margin	10.5%	-8.1%	-4.4%	-14.7%	-107.0%	-116.5%	-74.6%	-84.6%
Depreciation & Amortization	1.27M	37.50M	37.63M	37.70M	37.97M	34.69M	36.42M	2.42M
EPS Basic	-0.02	-0.33	-0.28	-0.58	-1.48	-2.53	-2.36	-1.47
EPS Diluted	-0.02	-0.33	-0.28	-0.58	-1.48	-2.53	-2.36	-1.47
Weighted Average Basic Shares	257.16M	210.95M	187.47M	182.78M	165.95M	138.46M	118.40M	116.89M
Weighted Average Diluted Shares	257.16M	210.95M	187.47M	182.78M	165.95M	138.46M	118.40M	116.89M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.